and long-term blockage, leading to functional and structural degeneration of the eccrine acini and thereby reducing sweat production. [13, 14] Skin irritation is a common limiting adverse event with aluminum chloride hexahydrate. [15, 16] Topical glycopyrrolate 2% improves HH because of its anticholinergic action by competitively binding the muscarinic acetylcholine receptors (Ach R). [17] Studies and case reports suggest good results in facial HH, whereas results on axillary HH were inconsistent. [18] [19] [20] Formaldehyde and glutaraldehyde are not commonly used in the treatment of primary focal HH because of their side effects such as localized skin irritation, allergic sensitization, and central nervous system toxicity. [16, 21] 
Injectable drugs
Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent. Various types of botulinum toxins have been tried in axillary and palmoplantar HH. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The administration of botulinum toxin requires multiple injections, and expertise to inject proper amount of the toxin at proper site and the procedure is painful. Apart from discomfort, it is costly and unaffordable by patients in resourcepoor settings. [33] [34] [35] Therapeutic failure owing to antibody formation is possible but extremely rare. [36] Device-based therapies Tap water iontophoresis (TPI) has been used as a mode of treatment for HH where an ionized substance is used for passing through the intact skin with the help of a device that delivers 15-20 mA of current through tap water. [37, 38] According to proposed hypotheses, it acts through the inhibition of sympathetic nerve transmission, ion deposition obstructing the sweat gland, and local alterations of pH inhibiting the sweat gland. [39] [40] [41] [42] Although TPI is found to be effective, it requires multiple sessions and maintenance therapy and is very time-consuming. [43] In addition, it can cause discomfort, vesiculation, and erythema. [44] Apart from TPI, various emerging modalities, for example, microwave technology, lasers, microneedle radiofrequency, and ultrasound, are recently used for a focused area of thermotherapy targeting the eccrine sweat glands. However, they are cumbersome and costly and require multiple sessions and expertise. [45] [46] [47] [48] [49] [50] 
Surgical
Sympathectomy is used especially in palmar HH. [51] Wolosker et al. evaluated quality of life in 453 patients prospectively for 5 years following endoscopic thoracic sympathectomy and found that 409 patients (90.3%) had improved quality of life and only 3.1% of the patients had worsening results. [52] In a study, more than 90% of patients had improved quality of life following sympathectomy and severe compensatory HH occurred in 5.4% of patients. Age did not affect these outcomes. [53] Although long-term improvement has been found in 79% of cases, the procedure has the drawback of development of compensatory HH in body areas that are not supplied by the upper nerve trunk. [53] In addition, there is a risk of surgery-related complications such as hemothorax, pneumothorax, Horner's syndrome, injury to the thoracic duct, and damage to the phrenic nerve. [54] For axillary HH, removal of axillary sweat glands by complete axillary curettage or liposuction has been tried, with success rate being 90%. [55, 56] However, the procedure needs skilled expertise and carries a risk of postprocedural complications of wound infection, scar formation, skin necrosis, and skin discoloration.
Oral systemic
All the above-mentioned therapeutic approaches show a specific safety and effective profile to control primary HH localized at the axilla, the palms of the hands, the soles of the feet, and the face, and some of them have also demonstrated efficacy in segmental compensatory HH. Generalized HH requires systemic treatment and other modalities can be used as an adjuvant. Oral anticholinergics, beta-blockers, benzodiazepines, methanthelinium bromide, and clonidine have been used for the treatment of HH and among them, oral anticholinergics are commonly used for HH. In this review, we will discuss various types of oral anticholinergics in the management of HH.
oral antIcHolInergIcs
HH is believed to be caused by overactive cholinergic input to the eccrine glands. [57] Overexpression of acetylcholine and α 7-nicotinic receptors in sympathetic ganglia has been demonstrated in HH patients. [58] Among oral anticholinergics, oxybutynin and glycopyrrolate have been studied widely for the management of HH.
Oxybutynin chloride
Over the years, several studies have demonstrated good results of oxybutynin in focal HH (axillary, facial, and palmoplantar) and generalized HH. [59] [60] [61] [62] [63] 
Mechanism of action
Oxybutynin is an oral anticholinergic medication having antagonistic action on M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor (Ach R). Its antimuscarinic effect on HH was first reported in 1988. [64, 65] Absorption Oxybutynin is rapidly absorbed, achieving the maximum concentration within an hour of oral intake after which plasma concentration decreases. The effective half-life of the drug is approximately 2-3 h. The absolute bioavailability of oxybutynin is reported to be about 6% (range, 1.6-10.9). Food delays the absorption and thereby increases the bioavailability of oxybutynin by 25%. [66] Distribution Oxybutynin is widely distributed in body tissues following systemic absorption. The major binding protein is α-1 acid glycoprotein. [64, 67, 68] The drug can cross blood-brain barrier.
Contd... 
Metabolism
Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. The metabolism results in one pharmacologically active product des-ethyl oxybutynin and a pharmacologically inactive product phenylcyclohexylglycolic acid. [64, 67, 68] Excretion Oxybutynin is extensively metabolized by the liver, with <0.1% of the administered dose excreted unchanged in the urine and <0.1% of the administered dose excreted as the metabolite des-ethyl oxybutynin. [64, 67, 68] 
Pregnancy status
Oxybutynin is a pregnancy category B drug. Oxybutynin chloride should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards. [64, 67, 68] 
Drug interactions
The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce side effects similar to anticholinergics should be avoided. [64, 67, 68] Due to anticholinergic effect on gastrointestinal (GI) motility, oxybutynin may alter the absorption of some concomitantly administered drugs. Ketoconazole being a potent CYP3A4 inhibitor increases the mean oxybutynin chloride plasma concentrations three-to four-fold. Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the oxybutynin's mean pharmacokinetic parameters (i.e., maximum concentration and area under the curve). [64, 67, 68] Dosage Different studies have followed the following regimen -oral oxybutynin 2.5 mg daily for the 1 st week, then 2.5 mg twice daily from day 8 to day 21, and 5 mg twice daily starting at day 22 up to 6 months for HH. [62, 63, 69] The drug can be taken with or without food.
Contraindications
• Absolute contraindication: Angle-closure glaucoma • Relative contraindication: Urinary retention, severe bladder outflow obstruction, gastric retention, GI obstruction, severe toxic megacolon, and hypersensitivity to the drug substance or other components of the product.
Side effect profile
Side effects are mainly due to the antimuscarinic effects of the drug. Dry mouth is experienced by 70%-100% of the patients treated with oxybutynin for HH. [70] Other adverse events observed include constipation in up to 31% of the patients and drowsiness in up to 18%, while a feeling of mild urinary retention, dry eyes, dizziness, blurred vision, diarrhea, mydriasis, dry skin, rash, photosensitivity, and flushing are seen rarely. [71] Monitoring
The anticholinergic effects are more frequent with doses over 15 mg/day. [72] A maximum dose of 10 mg/day reached through slow and progressive increase in dosage over a period of 3 weeks lowers the incidence of side effects, maintaining effectiveness and improving compliance to treatment. [63] Schedules of a 1.25-mg initial dose and an increase by 1.25 mg every 4 days up to 7.5 mg/day, or 2.5 mg/day for the 1 st week, 2.5 mg twice a day for the next 2 weeks, and 5 mg twice daily for the rest of the treatment have been successfully employed in literature. [73] Glycopyrrolate Glycopyrrolate (pyrrolidinium 3-[(cyclopentylhydroxy/ phenylacetyl) oxyl]-1, l-dimethyl bromide; glycopyrronium bromide) is a quaternary ammonium anticholinergic drug.
Mechanism of action
It competitively inhibits the action of acetylcholine at muscarinic receptors, which are prominent in glandular tissue. [74] It also induces smooth muscle relaxation. It is a known antisecretory drug, thereby reducing gastric, pharyngeal, tracheal, and bronchial secretions.
Absorption
Following oral administration, absorption from the GI tract is poor. Only 10%-25% of the drug is absorbed after oral intake. There is poor penetration of the drug across the blood-brain barrier. Both animal and human studies showed that placental transfer is limited. [75, 76] 
Metabolism and excretion
The major metabolic pathway is hydroxylation of the cyclopentyl ring and oxidation of the hydroxyl group in the mandelic acid residue which occurs in liver. The drug is chiefly excreted through urine and bile. [77] 
Dosage
In various studies, the effective mean dose of glycopyrrolate in adult patients with primary HH was 2 mg once to twice daily. [17, 78] The efficacy is higher in children than in adults in controlling HH (90% efficacy with a mean dosage of 2 mg daily), and significant side effects in children are unusual. [79] 
Drug interaction
The drug may antagonize the GI effects of prokinetic drugs (metoclopramide and domperidone).
Pregnancy category: Category B

Side effects
Side effects of glycopyrrolate include xerostomia, loss of taste, nausea, vomiting, constipation, erectile dysfunction, headache, urinary retention and hesitancy, tachycardia, feeling of bloating, ocular effects (dry eyes and cycloplegia), and dizziness. [17] Potentially fatal result can occur due to severe anaphylaxis.
Contraindication
The drug should be used with caution in those with close-angle glaucoma, bladder outflow obstruction, gastro-esophageal reflux disease, and cardiac insufficiency. It is contraindicated in those with myasthenia gravis, paralytic ileus, and pyloric stenosis. [17] Current literature on the efficacy of oral anticholinergic drugs are summarized in Tables 1 and 2. conclusIon Oral anticholinergic drugs are safe therapeutic options in the treatment of focal HH, especially in resource-poor settings. Oxybutynin and glycopyrrolate are currently available in the Indian market. The drugs need close monitoring for their side effect profile. The authors suggest a tailor-made dosing schedule in real clinical settings.
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